Practical management of antineoplastic-induced nausea and vomiting from antibody-drug conjugates: Insights from a Canadian expert panel [0.03%]
加拿大专家小组的见解：关于抗体药物偶联物致恶心呕吐的管理建议
Katarzyna J Jerzak,Stephanie Snow,Jan-Willem Henning et al.
Katarzyna J Jerzak et al.
ObjectiveTrastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) that are associated with clinically significant antineoplastic-induced nausea and vomiting (AINV), for which prophylaxis and manageme...
Immunotherapy "stop and go" and early discontinuation: A viable option in limited resources setting [0.03%]
免疫治疗的“启动与停止”及早期停药：资源有限条件下的可行选择
Nesrine Mejri,Myriam Saadi,Saif Baklouti et al.
Nesrine Mejri et al.
BackgroundImmunotherapy (IO) has transformed cancer treatment, improving survival across various malignancies. However, optimal treatment duration and dosing regimens remain unclear. In low- and middle-income countries like Tunisia, access ...
Identifying the limitations of the 2015 NIOSH vapor containment performance protocol for assessing closed system transfer devices [0.03%]
识别2015年NIOSH封闭系统传输设备蒸汽保含性能检验规程的局限性
Lori T Armistead,Stephen F Eckel
Lori T Armistead
IntroductionThe purpose of this series of three studies was to identify the limitations of the 2015 NIOSH Vapor Containment Performance Protocol for Assessing Closed System Transfer Devices (CSTDs) as well as the variables that may impact r...
Pain and metastatic cancer: Opioid prescribing practices and perceptions of their effectiveness [0.03%]
疼痛和转移性癌症：阿片类药物的处方实践及其有效性的认知
Khadija Ben Chaabane,Oussema Slimani,Raafa Ben Saada et al.
Khadija Ben Chaabane et al.
IntroductionPain management in patients with metastatic cancer is a major challenge. The aim of this study is to analyse opioid prescribing practices and evaluate their effectiveness as perceived by patients.MethodsA descriptive, prospectiv...
Rethinking centralised oncology pharmacy practice in the era of flat-dose immunotherapy, subcutaneous formulations and visit-administration day separation: A conceptual analysis and reform proposal [0.03%]
免疫治疗、皮下制剂和给药间隔期增加时代肿瘤药房集中管理模式的再思考：概念性分析与改革建议
Mauro Iannopollo
Mauro Iannopollo
ObjectiveTo examine whether the centralised Oncology Pharmacy Unit (OPU) model, established in the late 1990s for BSA-dependent cytotoxic compounding, remains fit for purpose in a contemporary oncology context dominated by flat-dose immunot...
CyFRASS-TR: A practical clinical predictive model for acute irinotecan-induced toxicity to enhance patient safety in solid tumor management [0.03%]
CyFRASS-TR：一种实用的临床预测模型，用于急性伊立替康引起的毒性，以增强实体瘤管理中的患者安全
Natharin Phattayanon,Assawin Dadookel,Nopphadol Nuntamool et al.
Natharin Phattayanon et al.
Irinotecan-based chemotherapy regimens are mainstay treatments for various solid tumors but are frequently complicated by acute toxicities that can impair treatment adherence and clinical outcomes. Personalized risk prediction is essential ...
Comparative pharmacovigilance signals for PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitor-associated hemophagocytic lymphohistiocytosis in the FAERS database [0.03%]
FAERS数据库中PD-1、PD-L1、CTLA-4和LAG-3免疫检查点抑制剂相关噬血细胞综合征的药物警戒信号的比较分析
Connor Frey
Connor Frey
BackgroundHemophagocytic lymphohistiocytosis (HLH) is a fulminant, hyperinflammatory syndrome increasingly recognized as a rare but devastating immune checkpoint inhibitors (ICI) toxicity. Given the lack of robust epidemiological data, a la...
Development of a unified approach to hazardous medicinal product management using closed system drug transfer devices [0.03%]
采用封闭系统药物传输设备管理危险药品的统一方法的研究开发工作
Paolo Amari,Karen Campbell,Mark Henry et al.
Paolo Amari et al.
ObjectiveTo provide an overview of global directives, standards, guidelines, and best practices in the management of hazardous medicinal products (HMPs) with closed system drug transfer devices (CSTDs).Data sourcesA literature review was pe...
Effectiveness and safety of first-line nivolumab-ipilimumab in metastatic renal cell carcinoma [0.03%]
一线使用纳武单抗-伊匹单抗治疗转移性肾细胞癌的有效性和安全性
Miguel Escario Gómez,Macarena García-Trevijano Cabetas,Clara Herranz Muñoz et al.
Miguel Escario Gómez et al.
Background/AimThe combination of nivolumab and ipilimumab is the standard first-line treatment for patients with metastatic renal cell carcinoma (mRCC) of intermediate or poor IMDC risk. However, real-world data in unselected populations re...
Retrospective analysis of inotuzumab-associated hepatotoxicity in adult patients with B-cell acute lymphoblastic leukemia: Expanding the Spectrum of calicheamicin syndrome [0.03%]
成人B细胞急性淋巴细胞白血病患者依图珠单抗相关性肝毒性的回顾性分析：扩大卡奇霉素综合征的范围
Derek Tai,Kareem Latif,Jasmine Cha et al.
Derek Tai et al.
BackgroundInotuzumab ozogamicin (InO), a CD22-directed antibody-drug conjugate, is effective in relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), but hepatotoxicity remains a recognized adverse effect, most commonly si...